伦敦市中心急诊科甲基苯丙胺中毒及相关危害就诊量增加
该研究回顾性分析伦敦两家急诊科2005–2018年毒理学就诊数据库,识别1244例甲基苯丙胺相关就诊,就诊数从2005年4例(占娱乐性药物就诊1.9%)升至2018年294例(16.2%)。2014–2018年850例病例系列中94.9%为男性,中位年龄35.1岁(范围16–67),最常见表现为激越(41.5%)、焦虑(35.2%)、幻觉(16.5%)和精神病性症状(14.8%)。54.2%合并使用GHB/GBL,合并使用似乎减轻神经精神症状,但与更高中毒严重评分及需高依赖/ICU级别护理相关。提示急诊应关注甲基苯丙胺与GHB/GBL共用的高风险人群。
要点
- 伦敦市中心两家急诊科甲基苯丙胺相关就诊从2005年4例(1.9%)升至2018年294例(16.2%),呈上升趋势。
- 2014–2018年850例中94.9%为男性,中位年龄35.1岁(范围16–67),神经精神症状最常见:激越41.5%、焦虑35.2%。
- 幻觉占16.5%、精神病性症状占14.8%,是甲基苯丙胺就诊的主要神经精神表现。
- 54.2%合并使用GHB/GBL,合并使用似乎减轻神经精神症状,但与更高Poisoning Severity Score及需高依赖/ICU级别护理相关。
适用人群与场景
- 伦敦两家急诊科2005–2018年所有毒理学相关就诊中涉及甲基苯丙胺的病例;2014–2018年850例病例系列中94.9%为男性,中位年龄35.1岁(范围16–67)。
- 原文未提及明确的纳入/排除标准或适用场景限制。
诊断标准与关键阈值
- 原文提及Poisoning Severity Score用于评估中毒严重程度,但未给出具体界值。
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 激越(41.5%)、焦虑(35.2%)、幻觉(16.5%)、精神病性症状(14.8%)为常见神经精神表现,需关注。
- 合并GHB/GBL使用与更高Poisoning Severity Score及需高依赖/ICU级别护理相关,应警惕。
研究设计与关键结果
- 研究类型:回顾性数据库分析及4年病例系列;样本量:1244例甲基苯丙胺相关就诊(趋势分析),850例(2014–2018年病例系列);中心数:伦敦两家急诊科。
- 主要趋势:甲基苯丙胺相关就诊从2005年4例(占所有娱乐性药物就诊1.9%)升至2018年294例(16.2%)。
- 病例系列人群:94.9%男性,中位年龄35.1岁(范围16–67);最常见临床特征为激越41.5%、焦虑35.2%、幻觉16.5%、精神病性症状14.8%。
- 54.2%合并使用GHB/GBL,合并使用似乎减轻神经精神症状,但与更高Poisoning Severity Score及需高依赖/ICU级别护理相关。
证据类型、等级与局限
- 证据类型:回顾性数据库分析及病例系列(原文未给出证据等级或推荐强度)。
- 局限:回顾性设计、仅两家中心、原文未提及样本量计算或混杂控制;原文指出需要进一步研究确定是否需要投入更多资源。
对床旁实践的改变
- 急诊应警惕甲基苯丙胺相关就诊增多趋势,尤其年轻男性出现激越、焦虑、幻觉或精神病性症状时。
- 对甲基苯丙胺中毒患者应询问GHB/GBL共使用,因共使用与更高中毒严重评分及需高依赖/ICU级别护理相关。
- 原文未提及具体治疗改变或适用/不适用人群的推荐。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Methamphetamine is a stimulant drug of abuse with increasing prevalence of use worldwide leading to public health concern. While previous research by our group a decade ago found no evidence of increasing harms associated with methamphetamine use in the UK, there are conflicting data on whether or not this is still the case. This paper aims to identify trends in methamphetamine-related harms and characterise the clinical features of ED presentations involving methamphetamine with gamma-hydroxybutyrate/gamma-butyrolactone (GHB/GBL).
METHODS: We retrospectively interrogated a database of all toxicology-related presentations to two central London EDs, extracting data on drugs involved for presentations relating to methamphetamine between 2005 and 2018 to enable analysis of trends. Further clinical data were extracted for presentations between 2014 and 2018 to give a 4-year case series.
RESULTS: A total of 1244 presentations involving the use of methamphetamine were identified. The number of presentations rose from 4 in 2005 (1.9% of all recreational drug presentations) to 294 (16.2%) in 2018. A total of 850 cases were identified for the 2014-2018 case series, 94.9% were male with a median (range) age of 35.1 (16-67) years. The most common clinical features in the methamphetamine presentations were neuropsychiatric: agitation (41.5%), anxiety (35.2%), hallucinations (16.5%) and psychosis (14.8%). GHB/GBL was co-used in 54.2% of presentations and appeared to attenuate the neuropsychiatric features seen. Use of GHB/GBL was associated with a higher Poisoning Severity Score and requirement for level 2/3 (high dependency unit/intensive care unit (ICU)) care.
CONCLUSION: ED attendances in central London relating to methamphetamine use have risen over the last decade. Combining methamphetamine with GHB/GBL is common and is associated with a higher Poisoning Severity Score and need for ICU level care. Further work is required to establish whether further resources need to be directed at this clinical and public health problem.
参考来源
- Harnett JT, Dargan PI, Dines AM, et al. Increasing emergency department attendances in central London with methamphetamine toxicity and associated harms. Emerg Med J. 2021. PMID: 34649939. doi:10.1136/emermed-2020-209550
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。